Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASK-HD-01-CS-101 AB-1001 in Early Manifest Huntington’s Disease
2024-510895-18-00Phase 2Authorised
- Sponsor
- AskBio
- Start
- Mar 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AAVrh10-CYP46A1 in Huntington disease (HD), sponsored by AskBio. Primary endpoint: Incidence of dose limiting toxicities, treatment emergent adverse events, and serious adverse events through Week 52. Planned start Mar 2024; status: authorised.
02
Drugs
AAVrh10-CYP46A1
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2024-510895-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510895-18-00.